Louisa Stone
Manager of Investor Relations
Replay available
Viridian Therapeutics, Inc. (NASDAQ: VRDN) Q1 2023 earnings conference call, held 2023-05-09. Replay captured from the company's public earnings webcast.

Manager of Investor Relations
President and Chief Executive Officer
Chief Financial and Business Officer
Senior Vice President, Corporate Affairs and Investor Relations
Chief Development Officer
Analyst, Wedbush Securities
Analyst, Wells Fargo
Analyst, Stifel
Watch the replay and follow the connected company analysis, news, and investor updates for Viridian Therapeutics, Inc..
WEBVTT 00:00:00.029 -- 00:00:03.490 Welcome to the Viridian Therapeutics first quarter 2023 00:00:03.490 -- 00:00:08.071 conference call. At this time, all participants are in a listen only mode. 00:00:08.071 -- 00:00:12.213 Later, we will conduct a question and answer session and instructions will be given at 00:00:12.213 -- 00:00:15.534 that time. As a reminder, this conference is being recorded. 00:00:15.534 -- 00:00:18.635 I would now like to hand the call over to Ms. 00:00:18.635 -- 00:00:22.696 Louisa Stone, Manager of Investor Relations for Viridian. 00:00:22.696 -- 00:00:25.056 Please go ahead. 00:00:29.056 -- 00:00:33.197 Thank you and welcome everyone to our first quarter 2023 00:00:33.197 -- 00:00:38.119 earnings conference call. The press release reporting our financial results and corporate 00:00:38.119 -- 00:00:45.101 updates is available on the investor's page of our corporate website at www.viridiantherapeutics.com. 00:00:47.582 -- 00:00:52.844 Joining me on the call this afternoon are Scott Myers, our President and Chief Executive 00:00:52.844 -- 00:00:57.991 Officer, Christian Humer, our Chief Financial and Business Officer, Dr. 00:00:57.991 -- 00:01:02.954 Deepa Rajagopalan, our Chief Product and Strategy Officer, Dr. 00:01:02.954 -- 00:01:08.558 Tom Chula, our Chief Development Officer, and Todd James, Senior Vice President, 00:01:08.558 -- 00:01:12.120 Corporate Affairs and Investor Relations. 00:01:12.120 -- 00:01:16.703 Before we begin, I would like to remind everyone that this conference call and webcast 00:01:16.703 -- 00:01:21.767 will contain forward-looking statements regarding our financial outlook in addition 00:01:21.767 -- 00:01:27.998 to regulatory, product development, and commercialization plans and research activities. 00:01:27.998...